Innate Pharma Granted U.S. Patent Titled ‘Multispecific antigen binding proteins’

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11208480.PN.&OS=PN/11208480&RS=PN/11208480

byBenzinga Newsdesk

December 28, 2021

1 minute read

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11208480.PN.&OS=PN/11208480&RS=PN/11208480

Stephens & Co. Maintains Overweight on AutoZone, Raises Price Target to $1850

By Benzinga Newsdesk

Today, 12:26 PM

Stephens & Co. analyst Daniel Imbro maintains AutoZone (NYSE:AZO) with a Overweight and raises the price target from $1700 to $1850.

AZO

Credit Suisse Initiates Coverage On Axon Enterprise with Outperform Rating, Announces Price Target of $169

By Benzinga Newsdesk

Today, 12:26 PM

Credit Suisse analyst Sami Badri initiates coverage on Axon Enterprise (NASDAQ:AXON) with a Outperform rating and announces Price Target of $169.

AXON

Prothena Touts Encouraging Data From Early-Stage Alzheimer’s Candidate

By Vandana Singh

Today, 12:26 PM

Prothena Corporation plc (NASDAQ:PRTA) announced topline data from the Phase 1 single ascending dose (SAD) study for PRX005 for Alzheimer’s disease. …

BMY

Cheniere Energy Q2 EPS $2.90 Misses $3.17 Estimate, Sales $8.01B Beat $6.39B Estimate

By Bill Haddad

Today, 12:26 PM

Cheniere Energy (AMEX:LNG) reported quarterly earnings of $2.90 per share which missed the analyst consensus estimate of $3.17 by 8.52 percent. This is a 323.08 percent increase over losses of $(1.30) per share from the

LNG

Innate Pharma Granted U.S. Patent Titled ‘Multispecific antigen binding proteins’

Related Posts

Stephens & Co. Maintains Overweight on AutoZone, Raises Price Target to $1850

Credit Suisse Initiates Coverage On Axon Enterprise with Outperform Rating, Announces Price Target of $169

Prothena Touts Encouraging Data From Early-Stage Alzheimer’s Candidate

Cheniere Energy Q2 EPS $2.90 Misses $3.17 Estimate, Sales $8.01B Beat $6.39B Estimate